Aptevo Therapeutics Soars 118.79% on AML Drug Success

Aptevo Therapeutics has skyrocketed in pre-market trading, rising by an impressive 118.79% on June 19, 2025. This surge is driven by the company's groundbreaking results from its Phase 1b/2 RAINIER trial, which showed that its lead drug, mipletamig, achieved an 85% remission rate in newly diagnosed acute myeloid leukemia (AML) patients who cannot tolerate intense chemotherapy.

Aptevo Therapeutics has announced that mipletamig, when combined with standard treatments venetoclax and azacitidine, delivered an 85% remission rate in newly diagnosed AML patients who cannot handle intense chemotherapy. This result is particularly significant for older or sicker patients who have limited treatment options. The drug's safety profile is also noteworthy, with no signs of cytokine release syndrome, a common and dangerous side effect of similar treatments.

Aptevo Therapeutics is pushing forward with Cohort 3 of the RAINIER trial, testing mipletamig at its highest dose yet, and it’s almost fully enrolled. The company is also set to present at the BIO International Convention in Boston from June 16-19, 2025, which could spark more buzz and potential partnerships. Additionally, Aptevo has other drugs in its pipeline, including ALG.APV-527, which is in Phase 1 for solid tumors, and a preclinical candidate, APVO442, for prostate cancer. These diversify their pipeline but also stretch their limited resources.